Table 1.
Characteristics of patients
| Characteristic | 80 mg (n = 39) | 120 mg (n = 3) |
|---|---|---|
| Age, median (range) | 53 (37–69) | 44 (37–55) |
| BMI, median (range) | 22.7 (17–31.8) | 26.0 (21.5–28.3) |
| Gender | ||
| Male | 20 (51.3) | 2 (66.7) |
| Female | 19 (48.7) | 1 (33.3) |
| ECOG performance status, n (%) | ||
| 0 | 3 (7.7) | 0 (0.0) |
| 1 | 36 (92.3) | 3 (100.0) |
| Primary site | ||
| Right colon | 13 (33.3) | 1 (33.3) |
| Left colon/rectum | 26 (66.7) | 2 (66.7) |
| Site of metastases | ||
| Liver | 27 (69.2) | 3 (100.0) |
| Lung | 23 (59.0) | 1 (33.3) |
| Lymph node | 18 (46.2) | 1 (33.3) |
| Peritoneum | 10 (25.6) | 0 (0.0) |
| Other | 6 (15.4) | 0 (0.0) |
| Chemo-refractory | 32 (82.1) | 3 (100.0) |
| Chemo-intolerant | 7 (17.9) | 0 (0.0) |
| Anti-EGFR, n (%) | 10 (25.6) | 2 (66.7) |
| Anti-VEGF, n (%) | 24 (61.5) | 1 (33.3) |
| Prior treatment lines | ||
| Median, range | 2 (2–5) | 3 (2–3) |
| =2 | 26 (66.7) | 1 (33.3) |
| ≥3 | 13 (33.3) | 2 (66.7) |
| MSI/MMR status | ||
| MSS/pMMR | 38 (97.4) | 0 (0) |
| MSI-L | 1 (2.6) | 0 (0) |
| RAS/BRAFV600E status | ||
| RAS and BRAFV600E wild | 13 (33.3) | 2 (66.7) |
| RAS mutant | 20 (51.3) | 1 (33.3) |
| BRAFV600E mutant | 2 (5.1) | 0 (0) |
| RAS or BRAF unknown | 4 (10.3) | 0 (0) |
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; MMR, mismatch repair; MSI, microsatellite instability; MSI-L, microsatellite instability low; MSS, microsatellite stable; pMMR, mismatch repair proficient